The global electronic drug delivery systems market size is expected to reach around US$ 12.1 billion by 2026 and growing at a CAGR of around 8.9% from forecast period 2019 to 2026.
Electronic drug delivery systems are smart devices that allow the patient to administer medicines in small quantities. These devices add value to traditional and non-automated devices and thereby improve the ease of administration, convenience, and portability. Key electronic drug delivery systems are electronic pens, wearable infusion pumps, electronic inhalers, and electronic autoinjectors. Electronic, wireless connected, and smart drug delivery devices are suitable for home applications. However, their advantages are also valuable within clinic and hospital settings. For instance, timely and appropriate insulin dosing are key concerns in diabetes patients and electronic insulin pen can help patients. Each dose through pen is recorded & logged and programmable dosing help to deliver an accurate amount of insulin after a particular period. Diabetes, cardiovascular diseases, multiple sclerosis, and COPD & asthma are the key indications for electronic drug delivery systems.
The rising demand for technologically advanced systems due to increasing awareness and chronic diseases is the key driving factor of the market across the globe. Furthermore, approval and commercialization of technologically advanced and innovative systems, ease of use, and accuracy in dose delivery are likely to boost the market growth during the forecast period. Rising prevalence of targeted diseases such as cardiovascular diseases, diabetes, and asthma & COPD due to unhealthy lifestyle is another factor responsible for propelling the market growth in the coming years. Autoinjectors and electronic pumps are the major devices used in such chronic diseases to deliver smaller doses. However, the higher cost over traditional drug delivery devices and non-availability of reimbursement in developing countries are likely to restrain the market growth during the forecast period.
By product, electronic wearable infusion pumps are dominating the electronic drug delivery systems market in terms of share. The segment is also anticipated to maintain its dominance during the forecast period due to wider availability and high demand from consumers in the market. Presence of various market players and their wide range of commercial products, application of infusion pumps in the delivery of medicine for the treatment of various chronic diseases, and rising awareness are the key factors propelling the segment growth. Key players operating in the electronic wearable infusion pumps segment are Medtronic, Tandem Diabetes Care, and United Therapeutics Corporation. In May 2019, United Therapeutics Corporation and DEKA Research & Development Corporation received the U.S. FDA approval 510k clearance for Remodulin injection, Rem Unity system. It is a lightweight, small, and durable pump indicated for the subcutaneous delivery of Remodulin in the treatment of Pulmonary Arterial Hypertension (PAH). The pump reduces the risk associated with bolus dosing due to pump failures and also provides a wide range of alerts, notifications, and alarms over currently available other pumps.
The diabetes segment accounted for the largest share of the market in 2018 by indication. Diabetes, cardiovascular diseases, multiple sclerosis, and COPD & asthma are the key segment of the electronic drug delivery systems market by indication. Wider availability of electronic insulin delivery devices, such as insulin pen and pumps, high prevalence of diabetes around the world, and investment by market players for the development and commercialization of devices for diabetes are the key factors responsible for the dominance of the diabetes segment in the market. For instance, according to the World Health Organization, the number of diabetic patients has risen to 422 million in 2014 from 108 million in 1980. Hence, rapidly increasing diabetes and other chronic diseases are likely to propel the electronic drug delivery systems market during the forecast period.
North America region dominated the regional segment in the year 2018 and is also expected to maintain its dominance during the forecast period. This can be attributed to the increasing incidence of chronic diseases in the region. According to the Centers for Disease Control and Prevention (CDC), 30.3 million people in America, about 1 in 10, had diabetes in 2017. Additionally, technological advancement and higher acceptance to the advanced technology, favorable reimbursement scenario, commercialization of various innovative drug delivery systems, and presence of key market players in the region are some of the major factors responsible for the dominance of the region in the market. In June 2018, AbbVie partnered with Eisai to launch an autoinjector pen for the Humira drug. The systems come with alert sounds, inspection window, and lock functions. However, Asia Pacific is anticipated to propel the market with the fastest rate during the forecast period due to presence of large targeted patient population, increasing investment by market players in the region due to supportive government regulations, and presence of emerging economies such as China, Russia, and India. Hence, increasing technological adoption, supportive reimbursement, rising chronic diseases, and commercialization of various devices are the key driving factors for the electronic drug delivery devices across the world.
The market research study on “Electronic Drug Delivery Systems Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”, offers a detailed insight on the global electronic drug delivery systems market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global electronic drug delivery systems market, its product, indication, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global electronic drug delivery systems market size, and segment markets by product, indication, and geography along with the information on companies operating in the market. The electronic drug delivery systems market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market size for different segments have been covered under the scope of the report.
The players profiled in the report include AstraZeneca, Insulet Corporation, Medtronic, F.Hoffmann-La Roche Ltd, Merck Group, Amgen, Bayer AG, Companion Medical, Tandem Diabetes Care, and Novo Nordisk A/S. The competitors of the industry are involved in research & development activities for providing more advanced and innovative solutions and also for the expansion of their geographical presence through collaborations and mergers to increase their market share.
Market By Product
Market By Indication
Market By Geography
Electronic drug delivery systems are smart devices that allow the patient to administer medicines in small quantities.
The rising demand for technologically advanced systems due to increasing awareness and chronic diseases is the main driver of the electronic drug delivery systems market.
According to Acumen Research and Consulting, the electronic drug delivery systems market value is anticipated to be worth around US$ 12.1 billion in 2026.
The electronic drug delivery systems market is anticipated to grow over 8.9% CAGR during the forecast period 2019 to 2026.
North America held maximum share in 2018 for electronic drug delivery systems market.
The diabetes segment accounted for the largest share of the market in 2018 by indication.
AstraZeneca, Insulet Corporation, Medtronic, F.Hoffmann-La Roche Ltd, Merck Group, Amgen, Bayer AG, and Companion Medical are the top players operating in the electronic drug delivery systems market.